PT  - JOURNAL ARTICLE
AU  - Wang, Yunhe
AU  - Alcalde-Herraiz, Marta
AU  - Güell, Kim López
AU  - Chen, Li
AU  - Mateu, Lourdes
AU  - Li, Chunxiao
AU  - Ali, Raghib
AU  - Wareham, Nicholas
AU  - Paredes, Roger
AU  - Prieto-Alhambra, Daniel
AU  - Xie, Junqing
TI  - Refinement of post-COVID condition core symptoms, subtypes, determinants, and health impacts: A cohort study integrating real-world data and patient-reported outcomes
AID  - 10.1101/2024.06.23.24309348
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.06.23.24309348
4099  - http://medrxiv.org/content/early/2024/06/24/2024.06.23.24309348.short
4100  - http://medrxiv.org/content/early/2024/06/24/2024.06.23.24309348.full
AB  - Background Post-COVID-19 condition (PCC) affects millions of people, and is an essential component of the long-term impact of COVID-19 during the post-pandemic era. Yet, consensus on clinical case definition and core components of PCC remains lacking, affecting our ability to inform research and evidence-based management. Our study aims 1) to identify the most specific symptoms for PCC , and identify clinical subtypes; 2) to evaluate both virus- and host-related determinants of PCC, and 3) assess the impact of PCC on physical and mental health.Methods We studied participants from UK Biobank who completed a health and wellbeing survey between June and September 2022. Participants reported the current conditions of the presence, duration, and functional limitations of 45 symptoms, using an online questionnaire designed specifically for COVID-19 research. SARS-CoV-2 infection status and disease history were obtained through linkage to surveillance data and electronic medical records, respectively. Participants reporting symptoms within 30 days after infection were excluded. The most specific PCC symptoms (MSS) were defined using two criteria: statistical significance (P < 0.05 after Bonferroni correction) and clinical relevance (absolute risk increase >5%). Propensity score weighting was used to control for confounding. Subtypes of PCC were then defined based on the MSS among the COVID-19 infected individuals. A multivariable regression was used to study pathogen- and host-related risk factors for PCC, and its impact on 13 physical and 4 mental health patient-reported functional outcomes.Findings 172,303 participants (mean age 68.9, 57.4% female) were included in the analysis, of whom 43,395 had PCR-confirmed COVID-19. We identified 10 MSS and classified four PCC subtypes: ENT subtype (30.1%), characterized by alterations in smell, taste, and hearing loss; cardiopulmonary subtype (10.4%), characterized by shortness of breath, postural tachycardia, chest tightness, and chest pressure; neurological subtype (23.5%), characterized by brain fog and difficulty speaking; and general fatigue subtype (38.0%), characterized by mild fatigue. A higher PCC risk was observed for patients with Wild-type variant, multiple infections, and severe acute COVID-19 illness, consistently across the four PCC subtypes. In addition, a range of factors, including socioeconomic deprivation, higher BMI, unhealthy lifestyle, and multiple chronic health conditions, were associated with increased PCC risk, except for age and sex. Conversely, vaccination was associated with a largely reduced PCC risk, particularly for the cardiopulmonary subtypes. Individuals with PCC experienced a much worse physical and mental health. Specifically, the cardiopulmonary subtype had the most pronounced adverse impact on function impairments, followed by neurological, mild fatigue, and ENT subtype. The most affected functions included the ability to concentrate, participate in day-to-day work, and emotional vulnerability to health problems.Interpretation PCC can be categorized into four distinct subtypes based on ten core symptoms. These subtypes appeared to share a majority of pathogen and host-related risk factors, but their impact on health varied markedly by subtype. Our findings could help refine current guidelines for precise PCC diagnosis and progression, enhance the identification of PCC subgroups for targeted research, and inform evidence-based policy making to tackle this new and debilitating condition.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDr Xie was funded through the Jardine-Oxford Graduate Scholarship and a titular Oxford Clarendon Fund Scholarship. Professor Prieto-Alhambra`s research group has received funding from the European Medicines Agency and Innovative Medicines Initiative. The research was partially supported by the Oxford National Institute for Health and Care Research (NIHR) Biomedical Research Centre. DPA is funded through a NIHR Senior Research Fellowship (Grant number SRF-2018-11-ST2-004). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:https://www.ukbiobank.ac.uk/I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesWe used data from the UK Biobank, a prospective population-based cohort with over 500,000 participants recruited between 2006 to 2010 across England, Scotland, and Wales. Besides the comprehensive baseline data, several external databases have been linked to UK Biobank participants to enable the follow-up of their health and disease outcomes.16,17 Details of the cohort profile and data linkages have been described previously.18